AAV9 Rep-Cap plasmid (serotype 9-specific AAV RC9 plasmids)

GeneMedi’s AAV9 Rep-Cap plasmid (serotype 9-specific AAV RC plasmid), also named AAV9-RC plasmid, or AAV-RC9 plasmid, is part of AAV9 packaging system. AAV9 Rep-Cap plamid supplies the AAV9 Rep (replication) proteins and the AAV9 capsid protein.

You can produce AAV9 paticle in 293T cell line in high titer using GeneMedi’s AAV9 Rep-Cap plasmid with GeneMedi’s AAV expression vector (overexpression or shRNA) and AAV helper plasmid.

The tissue tropism of AAV9 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.

AAV9 vector tissue tropism and gene transduction (serotype-specific AAV infection)

The tissue tropism of AAV9 vector has been validated in neuron(CNS), heart, muscle, retina and Pancreas, with potential applications in tissue-specific gene therapy.

Virus and titer: AAV9-GFP, AAV9-pTBG-Luciferase (AAV-Luc), 1.4×10¹² vg/ml
Animal: mouse, C57, 2 months
Gene delivery method: tail vein, 100μl
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy, in vivo imaging
Conclusion: intravenous injection of AAV9-pTBG-Luciferase (AAV-Luc) only infects liver cells and no non-specific infection

Virus and titer: AAV9-GFP, 1×10¹² vg/ml
Animal: Rat, SD, 2 months (Figure 8A, B, C); mouse, C57, 8 months (Figure 8D)
Infection site: heart
Gene delivery method: myocardial in situ injection, 10μl/site, 5 sites in total (Figure 8A, B, C);intraorbital intravenous injection (Figure 8D)
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

Virus and titer: AAV9-GFP, 1×10¹² vg/ml
Animal: Mouse, C57, 2 months
Infection site: Brain
Gene delivery method: Brain localization injection, 1μl
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

Virus and titer: AAV9-GFAP-GFP, 1×10¹² vg/ml
Animal: mouse, C57, 2 months
Infection site: Hippocampus
Gene delivery method: Brain localization injection, 1μl
Determine assay: 3 weeks post infection, wholemount, immunofluorescence microscopy

Virus and titer: AAV9-Luciferase (AAV-Luc), AAV9-GFP, 1×10¹² vg/ml
Animal: Mouse, C57, 2 months
Infection site: Skeletal muscles
Gene delivery method: Muscle in situ injection, 10μl/site, 4 sites in total
Determine assay: 4 weeks post infection, in vivo imaging, frozen section, immunofluorescence microscopy

Virus and titer: AAV-DJ-GFP, AAV9-GFP, 1×10¹² vg/ml
Animal: mouse, C57, 2 months
Infection site: Kidney
Gene delivery method: Multiple sites injection in kidney 10μl/site, 6 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×10¹² vg/ml
Animal: Nude mouse, 2 months
Infection site: Subcutaneous transplant of bowel cancer cells
Gene delivery method: Tumor injection, 10μl/site, 4 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

Virus and titer: AAV9-GFP, 1×10¹² vg/ml
Animal: mouse, C57, 2 months
Infection site: Mammary fat pad
Gene delivery method: Breast injection, 10μl/site, 4 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

Virus and titer: AAV2 (left) /AAV-DJ (middle) / AAV9 (right), 1×10¹² vg/ml
Animal: Nude mouse, 2 months
Infection site: Subcutaneous transplant of bowel cancer cells
Gene delivery method: Tumor injection, 10μl/site, 4 sites in total
Determine assay: 3 weeks post infection, frozen section, immunofluorescence microscopy

Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×10¹² vg/ml
Cells: HEK-293T
MOI: MOI=1×10⁴
Determine assay: 36 hours post infection, immunofluorescence microscopy